Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.500 AlteredExpression disease BEFREE We observed that melanoma PDXs resistant to CDK4/6i frequently displayed activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, and inhibition of this pathway improved CDK4/6i response in a p21-dependent manner. 31413145 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Functional analyses of differentially expressed genes (DEGs), obtained from the GEO (Gene Expression Omnibus) database, indicated that high proliferative and metastatic abilities are the main characteristics of melanoma and that the PI3K and MAPK pathways play essential roles in melanoma progression. 30385854 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE Alterations in the PI3K/AKT pathway occur in up to 70% of melanomas and are associated with disease progression. 31138602 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma. 29304903 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Collectively, our results indicated that Lyn plays a carcinogenic role in multiple cellular functions during melanoma development through regulating apoptosis and autophagy via the PI3K/Akt pathway and may be a valuable potential target for the clinical treatment of melanoma. 30854129 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE In conclusion, our study demonstrated that SCH-527123, a small-molecule antagonist for CXCR1 and CXCR2 inhibited cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway. 30340844 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Here, we show that constitutive activation of the small GTPase ARF6 (ARF6<sup>Q67L</sup>) is sufficient to accelerate metastasis in mice with BRAF<sup>V600E</sup>/Cdkn2a<sup>NULL</sup> melanoma at a similar incidence and severity to <i>Pten</i> loss, a major driver of PI3K activation and melanoma metastasis. 31048499 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma. 30793515 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. 31277584 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE STAT3-induced upregulation of SNHG17 contributed to the progression of melanoma by promoting the PI3K-AKT signaling. 31599425 2019
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE The mitogen‑activated protein kinase (MAPK) pathway, phosphoinositol‑3‑kinase (PI3K) pathway promote the development of melanoma through numerous genomic alterations on different components of these pathways. 29532857 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE Somatic alterations sequentially induced mitogen-activated protein kinase (MAPK) pathway activation, upregulation of telomerase, modulation of the chromatin landscape, G1/S checkpoint override, ramp-up of MAPK signaling, disruption of the p53 pathway, and activation of the PI3K pathway; no mutations were specifically associated with metastatic progression, as these pathways were perturbed during the evolution of primary melanomas. 29990500 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE In this study, we found that Ashitaba (<i>Angelica keiskei</i>) chalcones, 4-hydroxyderricin (4HD) and xanthoangelol (XAG), suppressed melanoma development by directly targeting both BRAFV600E and PI3K, which blocked the activation of downstream signaling. 29980517 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. 29210065 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. 29969627 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE MDA-19 Suppresses Progression of Melanoma Via Inhibiting the PI3K/Akt Pathway. 30613786 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. 30237495 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 GeneticVariation disease BEFREE Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals. 30325319 2018
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Although PI3K inhibition resulted in cytostatic effects on xenografted NRAS<sup>Q61H</sup> /PIK3CA<sup>H1047R</sup> melanoma, combined inhibition of MEK1/2 plus PI3K elicited significant melanoma regression. 28233937 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE These results demonstrate that the combination of HSP90 and PI3K/mTOR inhibitors could be an effective therapeutic strategy that target the main survival pathways in melanoma and must be considered to overcome resistance to BRAF inhibitors in melanoma patients. 28774796 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE This review describes the efficacy of therapies targeting the MAPK and PI3K/AKT signaling pathways in melanoma, details the mechanisms contributing to drug resistance, and discusses current approaches to improving outcomes further.Cancer 2017;123:2118-29.© 2017 American Cancer Society. 28543695 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Our data indicate that in mucosal melanomas RAS/NF1 alterations are frequent, implying a significant pathogenetic role for MAPK and potentially PI3K pathway activation in these tumors. 28380455 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Areas covered: This review provides a brief introduction of the PI3K-Akt signaling pathway and its role in melanoma development. 28064546 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. 28092667 2017
CUI: C0025202
Disease: melanoma
melanoma
0.500 Biomarker disease BEFREE Finally, we describe findings of high translational significance by demonstrating that Abl/Arg cooperate with PI3K/Akt/PTEN, a parallel pathway that is associated with intrinsic resistance to BRAFi and immunotherapy, as Abl/Arg and Akt inhibitors cooperate to prevent viability, cell cycle progression and in vivo growth of melanomas harboring mutant BRAF/PTEN. 28368422 2017